Avalo Therapeutics, Inc. ($AVTX)
Doyle Mittie โ Chief Medical Officer
Shares
679
Price
$0.00
Total Value
$0.00
Nearby Earnings
Mar 19, 2026
EPS:Est: -1.46
Mar 23, 2026
EPS:-1.02 (est: -1.46)-29.8%
Revenue:-$209.00K
Transaction Details
| Insider | Doyle Mittie |
|---|---|
| Title | Chief Medical Officer |
| Transaction Date | Apr 1, 2026 |
| Expiration Date | Jan 28, 2035 |
| Transaction Code | M Exercise/Conversion |
| Acquired/Disposed | Disposed |
| Security | Stock Option (Right to Buy) |
| Derivative | Yes |
| Direct/Indirect | Direct |
| Filing Date | Apr 3, 2026 |
| Shares Purchased | 679 |
| Price per Share | $0.00 |
| Total Value | $0.00 |
| Shares Owned After | 148,329 |
| Derivative | Derivative |
| Accession Number | 0001918845-26-000006 |
| Document | View SEC Filing |